LUTRIS PHARMA
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Lutris Pharma was established in 2015 and is based in Tel Aviv-yafo, Israel.
LUTRIS PHARMA
Social Links:
Industry:
Biotechnology First Aid Health Care Wellness
Founded:
2015-12-01
Address:
Tel Aviv-yafo, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.lutris-pharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Yoast WordPress SEO Plugin
Current Employees Featured
Founder
Official Site Inspections
http://www.lutris-pharma.com Semrush global rank: 6.13 M Semrush visits lastest month: 1.32 K
- Host name: box5760.bluehost.com
- IP address: 162.241.253.30
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Lutris Pharma"
Lutris Pharma - Crunchbase Company Profile & Funding
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small โฆSee details»
Management Team - Lutris Pharma
Dr. Noa Shelach is a senior biopharmaceutical executive with over 20 years of experience in drug development as well in VC investments. Prior to Lutris-Pharma, Dr. Shelach held CEO โฆSee details»
Board of Directors - Lutris Pharma
Prior to Lutris-Pharma, Dr. Shelach held CEO positions in leading private and public biopharmaceutical companies: NextGen Healthcare, Integra Holdings, Campus Bio (Held by: โฆSee details»
Lutris Pharma - LinkedIn
Lutris Pharmaโs lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients ...See details»
Lutris 2025 Company Profile: Valuation, Funding
Lutris General Information Description. Developer of therapeutic drugs designed to improve anti-cancer therapy. The company's drug paves the way for the administration of epidermal growth factor receptor (EGFR) inhibitors to โฆSee details»
Lutris Pharma - Company Profile
Lutris Pharmaโs lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR โฆSee details»
Lutris Pharma - Funding, Financials, Valuation & Investors
Lutris Pharma is funded by 5 investors. Peregrine Ventures and Columbus Venture Partners are the most recent investors. Which investors participated in the most funding rounds?See details»
Lutris Pharma - Israeli Startup | Startup Nation Finder
Mar 17, 2023 Lutris Pharma is developing the topical B-Raf inhibitor LUT014, a proprietary small molecule allowing administration of epidermal growth factor receptor (EGFR) inhibitors to โฆSee details»
Lutris Pharma | VentureRadar
Jan 28, 2025 Lutris-Pharma was established with a vision of improving anti-cancer therapy effectiveness as well as the quality of life for patients that are treated with EGFR (Epidermal โฆSee details»
Lutris Pharma Ltd. (Lutris Pharma Ltd.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
Mar 21, 2025 Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that โฆSee details»
Israel-based Lutris Pharma Secures $30 Mn Funding - startuprise.org
Jan 29, 2025 Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, has secured a $30 million โฆSee details»
Investors - Lutris Pharma
Lutris-Pharma is established by industry experts and leaders: Dr. Antoni Ribas, Pontifax and Arkin Holdings. Pontifax is a healthcare dedicated venture capital firm with over $600 million under โฆSee details»
Lutris Pharma Announces the Appointment of Seasoned Life โฆ
5 days ago Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, โฆSee details»
Lutris Pharma - Peregrine
Pharma & biotech Linkedin-in Globe Lutris Pharma is a clinical-stage biopharmaceutical company dedicated toenhancing the effectiveness of anti-cancer therapies while improving โฆSee details»
Lutris Pharma Announces the Appointment of Seasoned Life โฆ
5 days ago Lutris Pharma Noa Shelach, Ph.D. Chief Operating Officer [email protected] Rx Communications Group Michael Miller +1-917-633-6086 [email protected] SOURCE Lutris โฆSee details»
Contact Us - Lutris Pharma
Investor Relations Contact. Michael Miller. Rx Communications Group. 917 633 6086. [email protected]See details»
LUTRIS PHARMA โ Columbus Venture Partners
Lutris Pharmaโs lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR โฆSee details»
LUT-014 - Drug Targets, Indications, Patents - Synapse
About Lutris Pharma Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being โฆSee details»
Lutris Pharma Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the โฆSee details»
AACR: Topical gel relieves painful skin rash side effect caused by ...
6 days ago · Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life · Acne-like skin rash is a common โฆSee details»